Result of Accelerated Review Targeting Unmet Needs

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization in the European Union (EU) for Revolution Medicines (RVMD)'s oral treatment for metastatic pancreatic ductal adenocarcinoma (PDAC), 'Rasonque' (active ingredient: daraxonrasib, development code: RMC-6236). This review was conducted via the 'Phased Review' track of the 'Cancer Medicines Pathfinder' pilot program, which accelerates market entry for promising new drugs, significantly reducing the evaluation period from the usual 210+ days to less than 150 days. Following its Orphan Drug designation on April 20, 2026, this achievement symbolizes regulatory authorities opening a priority access pathway for the second-line pancreatic cancer treatment environment, which has suffered from extremely limited therapeutic alternatives.

Technical Breakthrough in RAS(ON) Multi-selective Inhibition Mechanism

Daraxonrasib, the core active substance of Rasonque, is the first oral 'multi-selective inhibitor' that directly blocks active RAS proteins that continuously drive tumor growth signals. It possesses an innovative mechanism that induces cancer cell death by inhibiting the binding of various RAS variants (G112D, G12V, G12R, etc.) that act as cancer-inducing switches by forming a complex with intracellular Cyclophilin A. While previous inhibitors from companies like Amgen or BMS were limited to the 'KRAS G12C' mutation, which accounts for only 1-2% of mutation frequency, Rasonque has secured a technical advantage by broadly controlling the major mutations that constitute over 90% of pancreatic cancer patients.

Unrivaled Survival Improvement Proven in Confirmatory Phase 3 Trial

This marketing authorization recommendation is based on data from a global, open-label, confirmatory Phase 3 trial (RASolute 302, NCT06625320) involving 500 patients with metastatic pancreatic ductal adenocarcinoma who failed previous systemic chemotherapy. In this study, where 92% of enrolled patients carried RAS G12 mutations, the Rasonque group recorded a median overall survival (mOS) of 12.4 months, nearly doubling the survival period compared to the 6.7 months observed in the standard chemotherapy control group. The median progression-free survival (mPFS) also improved twofold to 7.2 months compared to 3.6 months in the control group, and the primary adverse events—including diarrhea, rash, stomatitis, nausea, and vomiting—were reported at manageable levels, receiving a passing grade for its tolerability profile.

Commencement of European Commercialization and Shifts in Global Market Landscape

Following the adoption of the CHMP's positive opinion, final approval by the European Commission (EC) remains only a formality, which typically leads to official marketing authorization across Europe within 2 months. In particular, as Joint Clinical Assessment is being conducted in parallel under the EU Health Technology Assessment (EU HTA) regulations, the speed of price negotiations and early reimbursement listing in key countries such as Germany and France is expected to accelerate. Given its oral formulation and dosing convenience, Rasonque is expected to rapidly replace the status of standard-of-care cytotoxic chemotherapies (such as FOLFIRINOX) in the global pancreatic cancer second-line treatment market, which is valued at billions of dollars annually.